B. Riley Predicts Geron’s Q1 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Analysts at B. Riley issued their Q1 2025 EPS estimates for Geron in a note issued to investors on Wednesday, February 26th. B. Riley analyst K. Patel anticipates that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter. B. Riley currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. B. Riley also issued estimates for Geron’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.02) EPS.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million.

Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus cut their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday. HC Wainwright downgraded shares of Geron from a “buy” rating to a “neutral” rating in a research note on Wednesday. Needham & Company LLC decreased their price objective on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. Barclays restated an “overweight” rating and issued a $4.00 price target (down from $9.00) on shares of Geron in a research note on Thursday. Finally, Scotiabank dropped their target price on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a research report on Thursday. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Geron has a consensus rating of “Moderate Buy” and a consensus price target of $5.68.

Geron Price Performance

Shares of Geron stock opened at $1.74 on Friday. The stock has a market capitalization of $1.05 billion, a P/E ratio of -5.44 and a beta of 0.53. Geron has a 12 month low of $1.46 and a 12 month high of $5.34. The business has a 50 day simple moving average of $2.97 and a two-hundred day simple moving average of $3.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GERN. RTW Investments LP acquired a new stake in Geron in the 3rd quarter valued at approximately $200,268,000. Holocene Advisors LP bought a new stake in Geron during the third quarter worth approximately $82,498,000. Janus Henderson Group PLC grew its holdings in shares of Geron by 140.0% in the 3rd quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock worth $102,193,000 after acquiring an additional 13,163,889 shares during the last quarter. Vestal Point Capital LP raised its holdings in Geron by 947.6% during the 4th quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock worth $38,940,000 after buying an additional 9,950,000 shares during the period. Finally, Braidwell LP acquired a new stake in shares of Geron during the fourth quarter valued at approximately $24,802,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.